How PH-antastic to have not 1 but 2 🌟 pulmonary vascular meetings this week: #PHPN2025 and the PERT consortium, #PERT2025! Hope all @ats-pc.bsky.social
members and #PHPeeps attending have a safe trip and wonderful time! And don’t forget to tag us 😎 #PH #PVD #RV #PE @phassociation.org
members and #PHPeeps attending have a safe trip and wonderful time! And don’t forget to tag us 😎 #PH #PVD #RV #PE @phassociation.org
September 19, 2025 at 5:12 PM
How PH-antastic to have not 1 but 2 🌟 pulmonary vascular meetings this week: #PHPN2025 and the PERT consortium, #PERT2025! Hope all @ats-pc.bsky.social
members and #PHPeeps attending have a safe trip and wonderful time! And don’t forget to tag us 😎 #PH #PVD #RV #PE @phassociation.org
members and #PHPeeps attending have a safe trip and wonderful time! And don’t forget to tag us 😎 #PH #PVD #RV #PE @phassociation.org
🚨 ‼️ 🫀🫁 #PHPEEPS
Sharing an important and impactful study published today in @nejm.org : The #ZENITH trial of #sotatercept for high-risk patients with pulmonary arterial hypertension #pah.
Reduction in morbidity/mortality HR, 0.24; 95%CI, 0.13 to 0.43.
www.nejm.org/doi/full/10....
Sharing an important and impactful study published today in @nejm.org : The #ZENITH trial of #sotatercept for high-risk patients with pulmonary arterial hypertension #pah.
Reduction in morbidity/mortality HR, 0.24; 95%CI, 0.13 to 0.43.
www.nejm.org/doi/full/10....
Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death | NEJM
Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension. The eff...
www.nejm.org
March 31, 2025 at 3:48 PM
🚨 ‼️ 🫀🫁 #PHPEEPS
Sharing an important and impactful study published today in @nejm.org : The #ZENITH trial of #sotatercept for high-risk patients with pulmonary arterial hypertension #pah.
Reduction in morbidity/mortality HR, 0.24; 95%CI, 0.13 to 0.43.
www.nejm.org/doi/full/10....
Sharing an important and impactful study published today in @nejm.org : The #ZENITH trial of #sotatercept for high-risk patients with pulmonary arterial hypertension #pah.
Reduction in morbidity/mortality HR, 0.24; 95%CI, 0.13 to 0.43.
www.nejm.org/doi/full/10....
If this was scalable in low and middle-income countries, it would be a game-changer for the reduction of #Schistosomiasis associated #PulmonaryArterialHypertension, the most common (and neglected) form of #PulmonaryHypertension worldwide
#PAH
#PHPeeps
#PAH
#PHPeeps
FINALLY! Our discovery of a very specific and sensitive serological target for schistosomiasis diagnostics is UP. Please, enjoy our shout-out for glycans and the importance of anticipating diagnostics needs 🧪🩸🪱 journals.asm.org/doi/10.1128/...
Identification of a circulating carbohydrate antigen as a highly specific and sensitive target for schistosomiasis serology | Journal of Clinical Microbiology
The WHO 2030 roadmap deems diagnostics developments for schistosomiasis critically
needed. Here we present identification of an antibody target with superior performance
compared to traditionally used...
journals.asm.org
January 15, 2025 at 8:44 AM
If this was scalable in low and middle-income countries, it would be a game-changer for the reduction of #Schistosomiasis associated #PulmonaryArterialHypertension, the most common (and neglected) form of #PulmonaryHypertension worldwide
#PAH
#PHPeeps
#PAH
#PHPeeps
Finally a #PulmonaryHypertension post on Bluesky! 😀
Any #PHpeeps here?
Is there anybooodyyy?? 😅
#ThePeoplesVentricle
Any #PHpeeps here?
Is there anybooodyyy?? 😅
#ThePeoplesVentricle
The Impact of Group II Pulmonary Hypertension on Congestive Heart Failure Patients Admitted with ST Elevation Myocardial Infarction, A Nationwide Study https://www.medrxiv.org/content/10.1101/2023.11.21.23298866v1
The Impact of Group II Pulmonary Hypertension on Congestive Heart Failure Patients Admitted with ST Elevation Myocardial Infarction, A Nationwide Study https://www.medrxiv.org/content/10.1101/2023.11.21.23298866v1
Objective: To study the impact of group II pulmonary hypertension (PH) on the outcomes of patients a
www.medrxiv.org
November 27, 2023 at 9:47 PM
Finally a #PulmonaryHypertension post on Bluesky! 😀
Any #PHpeeps here?
Is there anybooodyyy?? 😅
#ThePeoplesVentricle
Any #PHpeeps here?
Is there anybooodyyy?? 😅
#ThePeoplesVentricle
I have to make a presentation about the most important original research on #PulmonaryHypertension in the last 12 mths (+/-2 months... we're flexible 😀)
#PHPeeps #RightVentricle #PeoplesVentricle's folks:
What's your favourite #PAH #PH original research of the last 12 months?
#PCCM
#PHPeeps #RightVentricle #PeoplesVentricle's folks:
What's your favourite #PAH #PH original research of the last 12 months?
#PCCM
September 25, 2023 at 9:07 PM
I have to make a presentation about the most important original research on #PulmonaryHypertension in the last 12 mths (+/-2 months... we're flexible 😀)
#PHPeeps #RightVentricle #PeoplesVentricle's folks:
What's your favourite #PAH #PH original research of the last 12 months?
#PCCM
#PHPeeps #RightVentricle #PeoplesVentricle's folks:
What's your favourite #PAH #PH original research of the last 12 months?
#PCCM
Word of advice for all phpeeps:
1. Don't switch text editors halfway through.
2. Agree on a citation style BEFORE writing.
3. Don't panic.
#phdchat
1. Don't switch text editors halfway through.
2. Agree on a citation style BEFORE writing.
3. Don't panic.
#phdchat
November 19, 2024 at 11:23 AM
Word of advice for all phpeeps:
1. Don't switch text editors halfway through.
2. Agree on a citation style BEFORE writing.
3. Don't panic.
#phdchat
1. Don't switch text editors halfway through.
2. Agree on a citation style BEFORE writing.
3. Don't panic.
#phdchat